Developing Novel Therapeutics
With National and International Research Institutes to Combat COVID-19 and Future Pandemics
A team, comprising Arockiasamy Arulandu, Sujatha Sunil, and Alessandro Marcello, together with Ruhvenile Biomedical OPC Pvt. Ltd., India, is working to develop novel therapeutics against COVID-19, through the design and synthesis of small, molecular inhibitors specifically targeting SARS-CoV-2 viral replication.
To target and block SARS-CoV-2 viral replication using novel small molecule inhibitors for COVID-19 therapy. The idea is to utilize the existing knowledge made available after the past SARS-CoV and MERS-CoV pandemics, and develop structure-based selective anti-SARS-CoV-2 therapeutics targeting pivotal proteases Mpro and PLpro to combat the ongoing COVID-19 pandemic and future outbreaks.
“Multidisciplinary, collaborative work with ICGEB and Ruhvenile”
Our international Italian collaborator Dr. Alessandro, ICGEB, Italy will screen the inhibitors against Italian isolates of SARS-CoV-2 at the ICGEB-Trieste, Italy facility. The screening assays are already in place.